SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY HETEROALKYLAMINE USEFUL FOR INHIBITING CHOLESTEROL ESTER TRANSFER PROTEIN ACTIVITY

Japanese Patent JP2007126460

A

To provide a compound and a composition effective for inhibiting the activity of a CETP [cholesterol ester transfer protein (plasma lipid transfer protein-1)] and useful for treating especially atherosclerosis and other coronary arterial diseases.

The compound is a polycyclic aryl and heteroaryl tertiary heteroalkylamine compound. For example, 3-[(3-fluorophenyl)-[[3-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol is cited as the polycyclic arylamine compound.

WO/2007/136323	A NOVEL PROCESS SUITABLE FOR LARGE-SCALE PRODUCTION OF PHENYL PROPAN DERIVATIVES OF FORMULA I
JPH01219015	ANHYDROUS CEROUS NITRATE-AMMONIUM NITRATE COMPLEX AND METHOD FOR PRODUCING THE SAME FORM CERIC AMMONIUM NITRATE
JP2023527315	Methods and compositions for targeting PD-L1

SIKORSKI JAMES A
DURLEY RICHARD C
MISCHKE DEBORAH A
REINHARD EMILY J
FOBIAN YVETTE M
TOLLEFSON MICHAEL B
WANG LIJUAN
GRAPPERHAUS MARGARET L
HICKORY BRIAN S
MASSA MARK A
NORTON MONICA B
VERNIER WILLIAM F
PARNAS BARRY L
PROMO MICHELE A
HAMME ASHTON T
SPANGLER DALE P
RUEPPEL MELVIN L

JP2006305973A

May 24, 2007

November 10, 2006

Click for automatic bibliography generation  

PHARMACIA CORP

C07C215/08; C07D251/46; A61K31/135; A61K31/136; A61K31/137; A61K31/145; A61K31/16; A61K31/166; A61K31/167; A61K31/17; A61K31/18; A61K31/196; A61K31/222; A61K31/235; A61K31/24; A61K31/245; A61K31/277; A61K31/33; A61K31/341; A61K31/343; A61K31/381; A61K31/395; A61K31/40; A61K31/403; A61K31/404; A61K31/4045; A61K31/41; A61K31/4164; A61K31/417; A61K31/4184; A61K31/42; A61K31/421; A61K31/4245; A61K31/426; A61K31/438; A61K31/44; A61K31/4402; A61K31/4406; A61K31/4409; A61K31/4412; A61K31/4418; A61K31/4453; A61K31/4465; A61K31/451; A61K31/455; A61K31/47; A61K31/472; A61K31/495; A61K31/496; A61K31/505; A61K31/53; A61K31/5375; A61K31/5377; A61K31/538; A61K31/695; A61P3/06; A61P9/08; A61P9/10; A61P43/00; B01J31/12; C07B57/00; C07B61/00; C07C213/04; C07C215/16; C07C215/28; C07C215/32; C07C215/50; C07C215/68; C07C215/76; C07C217/58; C07C217/82; C07C217/84; C07C217/86; C07C217/88; C07C217/90; C07C217/92; C07C219/06; C07C219/34; C07C221/00; C07C225/22; C07C229/60; C07C233/65; C07C233/69; C07C233/75; C07C233/80; C07C235/38; C07C235/56; C07C237/30; C07C237/38; C07C239/20; C07C255/16; C07C255/54; C07C255/55; C07C255/58; C07C271/28; C07C271/44; C07C271/58; C07C275/34; C07C275/40; C07C291/04; C07C311/04; C07C311/08; C07C311/21; C07C311/24; C07C311/60; C07C317/14; C07C317/32; C07C317/36; C07C319/20; C07C323/19; C07C323/20; C07C323/25; C07C323/31; C07C323/32; C07C323/36; C07C323/37; C07C323/44; C07C323/65; C07C327/22; C07D207/323; C07D207/335; C07D209/08; C07D209/14; C07D209/32; C07D209/86; C07D211/14; C07D211/62; C07D213/26; C07D213/30; C07D213/32; C07D213/38; C07D213/53; C07D213/61; C07D213/64; C07D213/643; C07D213/65; C07D213/66; C07D213/70; C07D213/80; C07D213/84; C07D213/85; C07D215/12; C07D215/60; C07D217/24; C07D225/08; C07D233/60; C07D233/64; C07D235/14; C07D239/26; C07D239/34; C07D251/16; C07D251/42; C07D257/04; C07D263/06; C07D265/16; C07D271/06; C07D277/20; C07D277/34; C07D295/10; C07D295/12; C07D295/135; C07D295/192; C07D307/14; C07D307/42; C07D307/52; C07D307/91; C07D309/12; C07D333/20; C07D333/28; C07D333/34; C07D333/56; C07D491/113; C07F7/18; C07D207/32

JPH11222428A	1999-08-17
JP2001517655A	2001-10-09
JP2001513790A	2001-09-04
JPH09255574A	1997-09-30
JPH0959155A	1997-03-04
JPH11222428A	1999-08-17
JP2001517655A	2001-10-09
JP2001513790A	2001-09-04
JPH09255574A	1997-09-30
JPH0959155A	1997-03-04

JPN6010040396, Ｔｅｔｒａｈｅｄｒｏｎ, Ｖｏｌ．５２，　Ｎｏ．４０, ｐ．１３０１７−１３０２６　（１９９６）．

Kazuo Shamoto
Shinjiro Ono
Yasushi Kobayashi
Akio Chiba
Hiroyuki Tomita
Hisako Nozaki

Previous Patent: 25-HYDROXY-16-ENE-26,27-BISHOMO-CHOLECALCIFEROLS

Next Patent: IMMUNOLOGICAL METHOD FOR TREATING GASTROINTESTINAL CANCER